879545-43-4

Basic information

• Product Name: (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone
• Synonyms: (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone
• CAS NO: 879545-43-4
• Molecular Weight: 323.617
• Mol File: 879545-43-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone(879545-43-4)
• EPA Substance Registry System: (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone(879545-43-4)

Safety Data

• Hazardous Substances Data: 879545-43-4(Hazardous Substances Data)

Usage

General Description

The chemical (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone, also known as bromochlorodor, is a ketone compound with the molecular formula C15H12BrClO. It is a white to off-white solid substance that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone has potential applications in the field of medicinal chemistry for the development of new drugs. It is also used as a building block in organic synthesis for the preparation of various chemical compounds. Additionally, bromochlorodor has been studied for its potential biological activities and pharmacological properties. However, the exact uses and effects of this compound may vary depending on the specific applications and research purposes.

Upstream product

• 100-41-4 ethylbenzene 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 

Downstream Products

• 879545-41-2 4-bromo-1-chloro-2-(4-ethylbenzyl)benzene 
• 358-23-6 trifluoromethylsulfonic anhydride 

Relevant articles and documents

(1 S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

Derivatives of a novel scaffold, C-phenyl 1-thio-d-glucitol, were prepared and evaluated for sodium-dependent glucose cotransporter (SGLT) 2 and SGLT1 inhibition activities. Optimization of substituents on the aromatic rings afforded five compounds with potent and selective SGLT2 inhibition activities. The compounds were evaluated for in vitro human metabolic stability, human serum protein binding (SPB), and Caco-2 permeability. Of them, (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (3p) exhibited potent SGLT2 inhibition activity (IC50 = 2.26 nM), with 1650-fold selectivity over SGLT1. Compound 3p showed good metabolic stability toward cryo-preserved human hepatic clearance, lower SPB, and moderate Caco-2 permeability. Since 3p should have acceptable human pharmacokinetics (PK) properties, it could be a clinical candidate for treating type 2 diabetes. We observed that compound 3p exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in animals. Phase II clinical trials of 3p (TS-071) are currently ongoing.

CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME

The present invention relates to physical crystal structures of compound of the formula (I): which is an H-1 form, H-2 form or S-PG form, pharmaceutical compositions containing structures of compound I and methods of treating diseases using compound I.